financetom
Business
financetom
/
Business
/
Potash miner K+S says US farmers to foot the bill for Trump's tariffs
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Potash miner K+S says US farmers to foot the bill for Trump's tariffs
Mar 13, 2025 5:30 AM

March 13 (Reuters) - Germany's K+S, which

exports potash to U.S. farmers from Canada, on Thursday said it

would pass any tariff-related costs onto customers, after its

2025 earnings forecast disappointed investors.

K+S produces around 8 million tonnes of potash products

yearly, exporting about 300,000 tonnes to the United States

mainly from Canada. Potash is primarily used in fertilizers.

"The tariffs will be passed on one-to-one to costs, meaning

the American farmer will ultimately foot the bill," CEO Burkhard

Lohr said in a press conference.

"If this becomes a sustained issue, we have the option to

serve the U.S. market from Germany at lower costs, as there are

currently no tariffs on European potash deliveries," he added.

Shares of the potash and salt miner were down around 5% as

of 1025 GMT, cutting into their year-to-date gains that stood at

35% as of Wednesday's close.

Warburg Research analyst Oliver Schwarz said those gains

were based on more positive "buy-side" expectations that had

counted on a continued strong earnings boost from higher potash

prices, which were dampened by the broadly stable outlook.

After a period of volatility caused by Russia's invasion of

Ukraine that shrank margins at potash miners, potash prices

began to stabilise in 2024.

Since December, they have been on an upward trend, rising

around $5 every week or two, K+S said.

It forecast earnings before interest, taxes, depreciation

and amortisation (EBITDA) of 500 million to 620 million euros

($543.35 million and $673.75 million) in 2025, compared with

557.7 million last year.

At its midpoint of 560 million euros, the outlook is above

analysts' average estimate of 537.5 million in a Vara poll, but

the buy-side had expected more, Schwarz said.

K+S topped market expectations for 2024 core earnings, in

contrast to North American rivals Mosaic and Nutrien ( NTR )

whose results missed them due to lower sales.

Lohr said the company expected the positive potash price

trend to continue, helped by strong demand from markets like

China which is tapping into its strategic reserves to meet

agricultural needs.

($1 = 0.9202 euros)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Once a beacon of stability, Vietnam to name third president in a year
Once a beacon of stability, Vietnam to name third president in a year
Mar 22, 2024
HANOI, March 22 (Reuters) - Communist-ruled Vietnam is seeking its third president in little more than a year after the resignation of Vo Van Thuong, who was only elected last year after the sudden dismissal of his predecessor. With accumulated foreign direct investment higher than its gross domestic product, Vietnam's stability is crucial to multinationals with large operations in the...
Cathie Wood's ARK Invest scoops up nearly 10,000 Reddit shares in debut
Cathie Wood's ARK Invest scoops up nearly 10,000 Reddit shares in debut
Mar 22, 2024
(Reuters) - Popular investor Cathie Wood's ARK Invest bought nearly 10,000 shares of Reddit ( RDDT ) in the social media platform's strong market debut on Thursday, an email from the asset manager showed. A total of 9,982 shares of the loss-making company was added to ARK Next Generation Internet ETF ( ARKW ) and ARK Fintech Innovation ETF (...
Hutchmed Begins Registration Stage for Phase 2/3 Trial of Investigational Autoimmune Disorder Drug
Hutchmed Begins Registration Stage for Phase 2/3 Trial of Investigational Autoimmune Disorder Drug
Mar 22, 2024
05:04 AM EDT, 03/22/2024 (MT Newswires) -- Hutchmed ( HCM ) said late Thursday it has started the registration stage for a phase 2/3 clinical trial of investigational drug sovleplenib for adult patients with warm antibody autoimmune hemolytic anemia in China. The move follows positive data from the proof-of-concept phase 2 stage of the trial and a consultation with the...
Japan's union group Rengo announces biggest wage hikes on record
Japan's union group Rengo announces biggest wage hikes on record
Mar 22, 2024
TOKYO (Reuters) -Japanese firms have agreed to raise pay by 5.25% this year, the biggest rise under comparable data since 2013, the country's largest union group Rengo confirmed on Friday. The results of the closely-watched wage negotiations are announced in several stages, in which the blue-chip firms are first to wrap up their talks in mid-March. The second announcement on...
Copyright 2023-2026 - www.financetom.com All Rights Reserved